Search

Amgen Inc

Closed

SectorHealthcare

407.09 -1.38

Overview

Share price change

24h

Current

Min

399.53

Max

412.98

Key metrics

By Trading Economics

Income

556M

2.4B

Sales

1.4B

10B

P/E

Sector Avg

25.03

47.946

EPS

6.29

Dividend yield

2.43

Profit margin

23.622

Employees

31,500

EBITDA

-416M

3.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-2.37% downside

Dividends

By Acuity

Dividend yield

Sector Avg

2.43%

2.27%

Next Earnings

3 Nov 2026

Next Dividend date

11 Dec 2026

Next Ex Dividend date

20 Nov 2026

Market Stats

By TradingEconomics

Market Cap

13B

218B

Previous open

408.47

Previous close

407.09

News Sentiment

By Acuity

51%

49%

248 / 340 Healthcare

Amgen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Oct 2026, 23:01 UTC

Amgen Inc shares are trading modestly higher in after-market hours, remaining above their 20-day moving average amid rising oil prices and inflation concerns.

7 Oct 2026, 23:11 UTC

Amgen Inc's shares declined slightly during after-market hours on Wednesday, following initial gains and positioning just below the regular session opening level.

6 Oct 2026, 23:15 UTC

Amgen Inc is trading modestly lower in after-market hours following a slight recovery earlier in the session, remaining in the middle of its one-month trading range.

2 Oct 2026, 20:07 UTC

Amgen Inc shares fell, continuing a downward trend with a cumulative drop since Thursday's close amid broader market declines.

1 Oct 2026, 23:05 UTC

Amgen Inc. is trading higher in after-market hours, despite a notable drop from an early high and marking its fourth consecutive session of lower closes.

30 Sept 2026, 23:40 UTC

Amgen Inc is trading modestly higher in after-market hours, supported by broader market gains and positive U.S. GDP and private sector job growth data.

29 Sept 2026, 20:07 UTC

News

Scotiabank raised Amgen's price target to $500 from $450, contributing to the stock's gains amid positive trial results for dazodalibep in systemic Sjögren's disease.

28 Sept 2026, 23:26 UTC

News

Amgen Inc's shares declined in after-market hours following the FDA's approval of Teva's Degevma, a biosimilar to Amgen's Xgeva, impacting its market position.

24 Sept 2026, 19:56 UTC

News

Amgen Inc shares are higher following positive topline results from its Phase 3 OASIZ 301 trial for dazodalibep in treating systemic Sjögren's disease.

23 Sept 2026, 23:41 UTC

Amgen Inc's shares are modestly higher in after-market trading, positioned near the midpoint of their one-month trading range.

22 Sept 2026, 20:01 UTC

Social Media
News

Amgen shares advanced as the company reported positive topline results from its Phase 3 OASIZ 301 study for Sjögren's disease, achieving its primary endpoint.

21 Sept 2026, 20:06 UTC

Amgen Inc is advancing today, continuing its upward trajectory since Friday's close, despite remaining below its 20-day moving average.

18 Sept 2026, 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

17 Sept 2026, 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

16 Sept 2026, 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

15 Sept 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

14 Sept 2026, 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

11 Sept 2026, 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

10 Sept 2026, 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

8 Sept 2026, 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4 Sept 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3 Sept 2026, 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2 Sept 2026, 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

1 Sept 2026, 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

31 Aug 2026, 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

28 Aug 2026, 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

27 Aug 2026, 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

26 Aug 2026, 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

25 Aug 2026, 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

24 Aug 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

-2.37% downside

12 Months Forecast

Average 403.292 USD  -2.37%

High 500 USD

Low 230 USD

Based on 27 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

27 ratings

9

Buy

16

Hold

2

Sell

Sentiment

By Acuity

248 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.